New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High C...(7 10-Q....),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
Date:12/10/2007
7 10-Q.
'/>"/>
| SOURCE Schering-Plough Copyright©2007 PR Newswire. All rights reserved |
Related medicine technology :
1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5OPAXIO 28TM 29 Combined with Alimta 28R 29 Well Tolerated in Dose Ranging Study of Patients with Advanced Non Small Cell Lung Cancer 4808 1OPAXIO 28TM 29 Combined with Alimta 28R 29 Well Tolerated in Dose Ranging Study of Patients with Advanced Non Small Cell Lung Cancer 4808 2OPAXIO 28TM 29 Combined with Alimta 28R 29 Well Tolerated in Dose Ranging Study of Patients with Advanced Non Small Cell Lung Cancer 4808 3Dysport proves safe effective anti wrinkle treatment UT Southwestern plastic surgeons find 53439 1Dysport proves safe effective anti wrinkle treatment UT Southwestern plastic surgeons find 53439 2Beckman Coulter Completes Acquisition of Olympus Lab Based Diagnostics Business 13318 1Beckman Coulter Completes Acquisition of Olympus Lab Based Diagnostics Business 13318 2
[0] Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease[0] ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program[0] The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
Other Medicine Technology:PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 7Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 8Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 9
Breaking Medicine News(10 mins):Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 2Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 3Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 4Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 5Health News:Lilly Announces the First 300-unit Vial of Insulin 2Health News:Lilly Announces the First 300-unit Vial of Insulin 3Health News:Lilly Announces the First 300-unit Vial of Insulin 4Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 2Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 3Health News:Prostate Hormone Therapy May Up Heart Risks 2Health News:Prostate Hormone Therapy May Up Heart Risks 3Health News:New approach to sickle-cell disease shows promise in mice 2
[0] City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans[0] Lilly Announces the First 300-unit Vial of Insulin[0] Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health[0] Prostate Hormone Therapy May Up Heart Risks[1] New approach to sickle-cell disease shows promise in mice
Other Medicine News:Health News:Dry Eye Syndrome Affects Visual Functions 2Health News:Combination of Depression and Type-2-diabetes Lethal for Heart Patients 2Health News:Health Care Systems for Critically Ill Patients Need Restructuring 2Health News:Want a Healthy Colon? Eat a Rainbow! 2Health News:Spain Launches Movement Against Skinny Fashion Models 2Health News:Spain Launches Movement Against Skinny Fashion Models 3
Dry Eye Syndrome Affects Visual FunctionsCombination of Depression and Type-2-diabetes Lethal for Heart PatientsHealth Care Systems for Critically Ill Patients Need RestructuringWant a Healthy Colon? Eat a Rainbow!Delhi Kids to Be Immunized Against PolioSpain Launches Movement Against Skinny Fashion Models
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |